Synthetic Biologics, Inc. (NYSEAMERICAN:SYN)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $0.65, but opened at $0.76. Synthetic Biologics shares last traded at $0.71, with a volume of 71,085 shares changing hands.

Separately, Maxim Group lowered shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a research note on Friday, October 2nd.

The business’s 50 day moving average is $0.37 and its 200-day moving average is $0.38.

Synthetic Biologics (NYSEAMERICAN:SYN) last posted its earnings results on Tuesday, November 10th. The company reported ($0.14) earnings per share (EPS) for the quarter.

An institutional investor recently bought a new position in Synthetic Biologics stock. Bridgeway Capital Management Inc. purchased a new position in Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 109,300 shares of the company’s stock, valued at approximately $56,000. Bridgeway Capital Management Inc. owned about 0.56% of Synthetic Biologics at the end of the most recent reporting period.

Synthetic Biologics Company Profile (NYSEAMERICAN:SYN)

Synthetic Biologics, Inc, a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients.

Read More: Retained Earnings

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.